Didn't find what you were looking for?

Self-propelled CNT microrockets enable rapid capture and isolation of CTCs. Publications 13 April 2015 Manuscript: Self-propelled Carbon Nanotube Based Microrockets for Rapid Capture and Isolation of Circulating Tumor Cells Self-propelled CNT microrockets rapidly capture and magnetically isolate circulating tumor cells, enabling faster liquid biopsy and early cancer detection. We demonstrated a novel carbon nanotube (CNT)-based microrocket that propels efficiently through the thrust generated by oxygen (O₂) bubbles. These self-propelled microrockets exhibit ultrafast propulsion in aqueous solutions as well as in Dulbecco’s modified Eagle’s medium (DMEM). The microrocket generated a driving force of over 231 and 300 pN in DMEM containing 4% hydrogen peroxide (H₂O₂). The speed and distance traveled by the microrocket can be controlled by adjusting the concentration of H₂O₂. The designed multifunctional microrocket has the ability to (i) rapidly target (~5 minutes) and efficiently capture (~85%) transferrin receptor–positive (TfR⁺) cancer cells from an artificial CTC-like suspension, (ii) magnetically isolate the captured cells from peripheral blood cells, and (iii) enable subsequent high-resolution imaging. We envision that such self-powered micromotors could provide a novel and effective approach for the rapid and efficient extraction of circulating tumor cells (CTCs) from biological fluids, supporting early cancer diagnosis and detection of recurrence. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

डॉ. जयंत खंदारे के नेतृत्व में कैंसर पहचान और मेटास्टेसिस नियंत्रण में नई पहल. Press Release 14 March 2026 डॉ. जयंत खंदारे के नेतृत्व में एक्टोरियस इनोवेशन्स ऍंड रिसर्च प्राइवेट लिमिटेड करेगी कैंसर की पहचान और मेटास्टेसिस नियंत्रण में नई क्रांतिकारी पहल एक्टोरियस इनोवेशन्स ऍंड रिसर्च प्राइवेट लिमिटेड, एक अग्रणी भारत-अमेरिकी जैव-प्रौद्योगिकी कंपनी है जो आधुनिक सर्कुलेटिंग टयूमर सेल्स (CTC) तकनीकों के माध्यम से ऑन्कोलॉजी के क्षेत्र में परिवर्तन ला रही है। कंपनी के संस्थापक, प्रबंध निदेशक और मुख्य वैज्ञानिक अधिकारी डॉ. जयंत खंदारे के दूरदर्शी नेतृत्व में कंपनी यह उल्लेखनीय प्रगति कर रही है। पूरी कहानी पढ़ने के लिए नीचे दिए गए लिंक पर क्लिक करें। Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Discover Actorius' journey. Learn how our innovation-driven, impact-obsessed start-up is revolutionizing early cancer detection. Our story so far An innovation-driven organisation 11000+ Patients Served 450+ Doctors Trust Us 100+ Publications 13+ Years of Excellence Innovation Driven Impact-obsessed Who we are About Actorius We innovate and create bio materials that have critical applications in the field of life sciences, drug delivery and medical diagnostics. We work with a vision to advance and improve human health. Trusted by: Mission, Vision & Purpose Innovating with Intent Our mission, vision, and purpose reflect our commitment to meaningful progress and measurable outcomes. Mission To develop innovative methodologies to develop diagnostic tests that provide early indicators of oncogenesis and enable informed treatment strategies. Vision To collectively advance and improve human health by developing biomedical innovations into practical applications that have wider reach, accessibility and affordability. Purpose To positively impact everyone, by developing solutions that have reduced time to decision making and providing precise information for a chosen course of action. Our Values What We Stand For Our values define our commitment to rigorous science, responsibility, and meaningful impact. Work on challenges with cutting-edge science and innovation. Work towards making it accessible and affordable to the masses. Ensure critical clinical validations for every outcome. Bio-materials with high specificity, efficiency and sensitivity. Scientific disciplines with interdisciplinary intelligence at the core. Take every little step to ensure cancer patient’s lives are saved. Focused on creating novel cancer diagnostic tests. Know more Rigour in every action. Every product undergoes intense design and development. Leaving no stone unturned. We follow the most stringent quality norms like ISO13485 and regulatory requirements. Passionate and emphatic. We are committed to developing solutions for unmet medical needs. We build high-risk innovative products, which have a very long life-cycle, using novel biomaterials. Detect cancer relapse early, when it can be cured. We are committed to bringing stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care. India has a breakthrough in early cancer detection. Know More

Chemo-specific designs for the enumeration of CTCs: advances in liquid biopsy Publications 18 December 2020 Manuscript: Chemo-specific designs for the enumeration of circulating tumor cells: advances in liquid biopsy Review on chemo-specific nano/micro substrates for efficient CTC isolation, enabling liquid biopsy, metastasis detection, and real-time cancer monitoring. Advanced materials and chemo-specific designs at the nano- and micrometer scale have ensured revolutionary progress in next-generation clinically relevant technologies. For example, isolating a rare population of cells, such as circulating tumor cells (CTCs) from blood among billions of other blood cells, is one of the most complex scientific challenges in cancer diagnostics. Achieving this level of exceptional specificity for extracellular biomarker interactions requires chemical tunability through the use of advanced materials and multistep reactions in both solution and insoluble states. This review delineates the chemo-specific substrates, chemical methods, and structure–activity relationships (SARs) of chemical platforms used for the isolation and enumeration of CTCs, thereby advancing the relevance of liquid biopsy in cancer diagnostics and disease management. We highlight the synthesis of cell-specific, tumor biomarker-based chemo-specific substrates utilizing functionalized linkers through chemistry-based conjugation strategies. The capacity of these nano- and micro-scale substrates to enhance interaction specificity and efficiency with targeted tumor cells is discussed in detail. Furthermore, this review emphasizes the importance of CTC capture and downstream processes involving genotypic and phenotypic CTC analysis in real time. These approaches enable early detection of metastasis progression, evaluation of chemotherapy treatment response, and monitoring of progression-free survival (PFS), disease-free survival (DFS), and overall survival (OS) in cancer patients. Royal Society of chemistry. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Explore career opportunities at Actorius Innovations. Join us to innovate with intent and make a difference in patient lives. Careers Join us to be a part of our Journey Innovation Driven Impact-obsessed Who we are About Actorius We innovate and create bio materials that have critical applications in the field of life sciences, drug delivery and medical diagnostics. We work with a vision to advance and improve human health. Trusted by: Mission, Vision & Purpose Innovating with Intent Our mission, vision, and purpose reflect our commitment to meaningful progress and measurable outcomes. Mission To develop innovative methodologies to develop diagnostic tests that provide early indicators of oncogenesis and enable informed treatment strategies. Vision To collectively advance and improve human health by developing biomedical innovations into practical applications that have wider reach, accessibility and affordability. Purpose To positively impact everyone, by developing solutions that have reduced time to decision making and providing precise information for a chosen course of action. Our Culture For us, at Actorius, commitment to team work comes first. We have a flat hierarchy. We believe that it takes all sorts to make a formidable team. That’s why we are, at times, open to welcoming passionate and driven people to be a part of our growing team. Team Building We are open to welcoming passionate and driven people to be a part of our growing team. We hold off-sites and affiliation events to bring together members of the team. We take pride in investing in individualised talent development programme and mentoring. Our People Driven by People, Defined by Purpose. Whether you’re an experienced professional or a recent graduate, working with Actorius could be an enriching experience and rewarding next step in your career. Our Values What We Stand For Our values define our commitment to rigorous science, responsibility, and meaningful impact. Work on challenges with cutting-edge science and innovation. Work towards making it accessible and affordable to the masses. Ensure critical clinical validations for every outcome. Bio-materials with high specificity, efficiency and sensitivity. Scientific disciplines with interdisciplinary intelligence at the core. Take every little step to ensure cancer patient’s lives are saved. 50+ and counting We’re looking for dynamic thinkers and doers to help us make a difference to patient lives. Apply Now Jobs Current Job Openings Current openings at Actorius Innovations and Research Didn't find any relevant openings? You think you are driven by a vision to positively changes the lives of cancer patients? or you have a passion for research, fill in the following form. if we have a position that we think you're suitable for, we'll reach out to you. Apply Proactively

Magnetic nanogels enable optimized capture of circulating tumor cells from blood. Publications 11 February 2018 Manuscript: Optimizing Circulating Tumor Cells’ Capture Efficiency of Magnetic Nanogels by Transferrin Decoration Magnetic nanogels with optimized PEG–transferrin linkers achieve over 80% efficiency in selectively capturing circulating tumor cells from blood. Magnetic nanogels (MNGs) are designed with the necessary features to function as highly efficient trapping materials for the challenging task of selectively capturing circulating tumor cells (CTCs) from the bloodstream. A key factor in this process is the ability to discriminate CTCs from hematological cells, which can be optimized by finely tuning the polymers used to link the targeting moiety to the MNGs. Here, we describe the relationship between the capturing efficiency of CTCs with overexpressed transferrin receptors and the different strategies used in polymer linkers to decorate these MNGs with transferrin (Tf). Heterobifunctional polyethylene glycol (PEG) linkers with varying molecular weights were coupled to transferrin in different ratios. Optimal results, with over 80% CTC capture efficiency, were obtained when three PEG linkers with a length of eight ethylene glycol (EG) units were used. These findings highlight the crucial role of linker design in developing efficient CTC-sorting systems. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Marathi news report on early cancer recurrence detection using liquid biopsy. Press Release 29 August 2019 Early Detection of Cancer Recurrence Now Possible in Marathi A feature highlighting innovative liquid biopsy technology that enables early detection of cancer recurrence, with expert insights from Dr. Jayant Khandare of Actorius Innovations and Research in Marathi News Paper This news feature discusses advancements in cancer diagnostics that make early detection of recurrence possible through cutting-edge liquid biopsy techniques. Dr. Jayant Khandare explains how circulating tumor cell–based testing can help monitor disease progression, guide treatment decisions, and improve patient outcomes. The report emphasizes the growing cancer burden and the importance of accessible, minimally invasive diagnostic solutions in India. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTCs track residual disease and therapy response in breast cancer patients. Publications 6 June 2023 ASCO 2023: Effect of circulating tumor cells distribution in treatment naive and treated patients with advance stage breast cancer on disease burden. A study of 417 breast cancer patients shows tracking circulating tumor cells (CTCs) effectively monitors therapy response and recurrence risk. Background Breast malignancies are a leading cause of cancer-related mortalities and show an ascending incidence rate. Despite advancements in our understanding of the disease, its clinical outcome is often dismal. This largely remains owing to the characteristic wide window of relapse, spanning months to decades after primary treatment. Therefore, continuous monitoring of the disease is an offered choice to detect metastatic progression and recurrence. Circulating tumor cells (CTCs) have emerged as a powerful prognostic tool to predict the disease outcome in many epithelial cancers. CTCs are a real-time surrogate biomarker accounting for minimal residual disease (MRD) which is often missed in CT PET scanning. This leads to a progression of metastasis when the patient is often considered as 'clinically disease free'. Here, we analyzed the presence of CTCs in treatment-naive and chemo-recipient breast cancer patients. Methods In this retrospective study on 417 breast cancer patients, CTCs were isolated from 1.5 ml of blood using the Drug Controller General of India (DCGI) approved OncoDiscover CTC test. This platform contains affinity-based magnetic nanoparticles to mediate EpCAM-based CTC isolation. CTCs were detected as CK18+, DAPI+ and CD45- cells based on an automated digital imaging platform. Results 42.6% (n=178) of patients were clinically at a progressive stage (stage II and III) and treatment-naive. On the other hand, 47.4% of patients received treatment including surgery and chemotherapy. CTCs were not observed in 5.6% (n=10) of the treatment-naive population, while 32% (n=75) of patients who received therapy did not show CTCs. The mean CTC number in treatment-naive patients was 15, while the mean CTC count in patients receiving therapy was drastically reduced to 2. This implied that therapy effectively countered the tumor progression and reduced the shedding of tumor cells in circulation. The distribution of CTC in treatment-naive patients exhibited a bimodal trend centered at values of 10 and 50, suggesting two distinct populations of patients with respect to CTC count. CTC count did not show any correlation with the age in both population groups. Surprisingly, CTC count in younger patients (20-50 years) was 50% higher compared to the older population (50-75 years). Conclusions The presence of CTCs in treatment-naive, progressive breast cancer patients indicated biologically aggravated disease. Although therapeutic intervention drastically reduced the CTC burden, their presence in a large population was suggestive of an MRD and the likelihood of recurrence after discontinuation of therapy. A distinct pattern of CTC occurrences in Tx naive and Tx recipient patients suggested that CTCs can be an important clinical indicator to monitor the therapy response, progression, and residual disease. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTCs and PD-L1 after radiotherapy indicate MRD and possible tumor re-invasion. Publications 25 November 2024 ISLB 2024: Transit of Circulating Tumor Cells (CTC) Post Radiotherapy at Irradiated Tumor Regions in Pan-cancer Patients Study links radiotherapy exposure with circulating tumor cells and PD-L1 expression, indicating possible minimal residual disease and metastatic risk. Introduction The presence of circulating tumor cells (CTCs) is a predictor of minimal residual disease (MRD) and treatment outcomes. Abscopal effects of targeted intraoperative radiotherapy have been observed clinically, and the tumor microenvironment may influence these outcomes. Recent reports have shown activation and transit of CTCs following simulated radiotherapy from irradiated regions in vitro. Thus, the cellular extravasation and invasion phenotype cascade of CTCs in irradiated tumor regions could be highly concerning and raises several clinical questions. For the first time, we retrospectively analyzed patients who underwent radiotherapy to observe a clinical correlation between the presence of CTCs and overexpression of the PD-L1 protein in blood circulation as an indicator of minimal residual disease and a potential radiotherapy-associated effect. Methods A cohort of 26 pan-cancer patients (female = 10, male = 16) was analyzed, including cases of colorectal cancer (n = 4), lung cancer (n = 4), endometrial cancer (n = 4), head and neck cancer (n = 4), pancreatic cancer (n = 1), ovarian cancer (n = 1), renal cell carcinoma (n = 4), breast cancer (n = 2), and bone cancer (n = 2). Blood samples were analyzed retrospectively based on clinical and treatment history. Enumeration of CTCs was performed using the immunomagnetic multi-component OncoDiscover platform approved by CDSCO India, mediated by anti-EpCAM antibodies. CTCs were identified based on the presence of CK18+, PD-L1+, DAPI+, and CD45− staining using an automated Zeiss microscope in 1.5 ml of blood samples. Results In the retrospective analysis, a total of 88% (23/26) of patients showed the presence of CTCs in 1.5 ml of blood. Among these patients, 46% (n = 12/26) had undergone radiotherapy at some point during their treatment history. Three patients had received focused radiotherapy for brain metastasis with primary cancers of head and neck (1 case) and endometrium (2 cases). Among patients who underwent radiotherapy, 88% (8/9) were observed to have at least one CTC along with PD-L1 overexpression in at least one CTC. In addition, one patient who underwent radiotherapy showed the presence of a CTC cluster. Conclusions For the first time, we demonstrate the association of CTCs following radiotherapy in irradiated tumor regions. The disseminated CTCs may enhance tumor cell reinvasion through active transit in circulation, supported by a favorable microenvironmental milieu. Further validation with larger clinical cohorts across multiple cancer types is required. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTCs as biomarkers for relapse detection in rectal cancer with liver metastasis. Publications 29 June 2024 Manuscript: Circulating Tumor Cells as Biomarkers for Relapse Detection in Rectal Cancer with Liver Metastasis: Insights from a Case Report In this case report we demonstrate the utility of CTC as a sensitive marker to detect MRD. CTCs play a crucial role in the context of MRD in colorectal cancer, offering a valuable biomarker for prognosis, treatment monitoring, and early detection of recurrence. A 70-year-old female diagnosed case of rectal carcinoma (T3N2M0) received FOLFOX × 2 cycles followed by CAPOX × 2 cycles. She then underwent chemoradiation using capecitabine as a radiosensitiser, followed by laparoscopic tumor resection. The histopathology report showed tumour regression grade 2 (TRG2) response. Subsequently, the patient received 4 cycles of CAPOX but developed grade 2 peripheral neuropathy, leading to modification of her treatment to capecitabine alone for an additional 2 cycles. A whole-body positron emission tomography–computed tomography (PET-CT) scan at this stage showed no evidence of disease. However, a liquid biopsy test detected the presence of two circulating tumor cells (CTCs). An MRI of the abdomen and pelvis was conducted, revealing multiple live lesions (4 mm–6 mm) in segment IV/VIII of the liver, with no sign of local disease. To manage liver metastasis, the patient received 1 cycle of FOLFIRI while awaiting selective internal radiotherapy (SIRT), followed by 5 cycles of FOLFIRI. Three years later, her PET scans were observed to be completely normal. This case highlights the critical role of CTCs as a biomarker for detecting minimal residual disease (MRD) or relapse. Without CTC monitoring, the liver metastasis—which was successfully treated with SIRT—would likely have been missed under standard cancer care guidelines. As of today, the patient is completely disease-free, underscoring the importance of thorough investigation using advanced CTC liquid biopsy biomarkers in managing rectal cancer with liver metastasis. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Explore our innovative patents. Discover the power of innovation and precision in our groundbreaking patent solutions. Patents & Certifications Proof of Precision. Power of Innovation. We are committed to utmost scientific rigour. Every product at Actorius Innovations and Research undergoes intense design and development. Our products are patented worldwide. We follow the most stringent quality norms (ISO13485) and applicable regulatory requirements for medical devices (rules 2017) 20 October 2025 Non-hemolytic compositions and methods of use for recovering disease-causing toxic constituents in the blood A non-hemolytic adsorbent composition designed to isolate, quantify, and remove disease-causing toxic constituents from blood, supporting disease identification, monitoring, and therapeutic efficacy validation. Read More 13 February 2023 Devices and methods for recovering disease-causing toxic constituents in the blood A cost-effective, high-efficiency nanosystem for rapid circulating tumor cell enumeration. Read More 22 April 2021 Multifunctional magneto-polymeric nanosystems for rapid targeting, isolation, detection and simultaneous imaging of circulating tumor cells A multifunctional magneto-polymeric nanosystem for rapid targeting, isolation, detection, and imaging of circulating tumor cells to support cancer diagnostics and monitoring. Read More 26 February 2020 Polymer based formulation for release of drugs and bioactives at specific GIT sites. A polymer-based formulation designed for targeted release of drugs and bioactives at specific gastrointestinal sites, including the stomach, intestine, and colon. Read More First Prev 1 Page 1 Next Last

Large study shows CTCs and clusters predict aggressive epithelial cancer progression. Publications 10 April 2024 AACR 2024: Distribution prophecy of circulating tumor cell clusters in CTC populace patients of epithelial cancers Large-scale analysis of circulating tumor cells and clusters reveals their role in predicting aggressive epithelial cancers and treatment resistance. Background: The role of circulating tumor cells (CTCs) in metastatic cancers for predicting overall survival has been well established. The effectiveness of three- or six-month adjuvant therapy in colorectal cancer estimation has shown an association between CTCs and the emergence of resistant cell clones. The presence of CTC clusters indicates increased aggressiveness in epithelial cancers. However, the presence of CTC clusters has not been evaluated in large patient populations. Here, we demonstrate the distribution and prognostic significance of CTCs and CTC clusters in epithelial cancer patients. Methods: Retrospectively, blood samples from 3458 patients were analyzed for the presence and distribution of CTCs and CTC clusters using the DCGI-approved OncoDiscover platform, which uses an immunomagnetic multicomponent system mediated by an anti-EpCAM antibody. A total of 1.5 mL of peripheral blood was analyzed to capture cells and clusters from head and neck, breast, and lung cancer patients. The sensitivity, specificity, and accuracy of the OncoDiscover assay had been previously established. CTCs and clusters were identified using CK18 positive, DAPI positive, and CD45 negative staining with automated motorized fluorescence microscopy. CTC clusters were defined as the presence of two or more CTCs bound together. Results: Out of 3458 epithelial cancer patients, 65.52% (2262 patients) showed the presence of CTCs, with CTC numbers varying from 1–9 per 1.5 mL of blood. Meanwhile, 7.54% of patients showed CTC clusters, corresponding to 261 clusters. The total number of captured CTCs and clusters was 19,345, with a mean distribution of 5.59. Among these, CTCs accounted for 19,037 (98.41%), while clusters accounted for 308 (1.59%). The highest number of CTCs was observed in head and neck cancers (52.98%) and breast cancers (22.75%), followed by lung cancer (5.65%). In contrast, clusters were most frequently observed in breast cancers (26.95%), followed by lung cancer (16.23%). Conclusions: The frequency and distribution of CTCs and CTC clusters were evaluated in epithelial cancers. Patients with CTCs alone and those with both CTCs and CTC clusters represent a more aggressive disease state and a higher likelihood of disease progression. The effectiveness of adjuvant therapy in epithelial cancers may be estimated using CTC and cluster analysis, as their presence may indicate treatment resistance and the emergence of resistant cell clones. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe